Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 20, 2024HIV Medicine

Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV

View Full Paper
Ask AI
Bookmark
Share

Authors

LRLuis Ramos‐RupertoMRMaría del Mar Arcos RuedaRBRosa de Miguel Buckley

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ramos‐Ruperto et al. (2024) studied this question.

synapsesocial.com/papers/68e786ffb6db6435876f9c14https://doi.org/10.1111/hiv.13617
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/ml and history of K103N mutation2026
  2. 2Virological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial2026
  3. 3Real world use of dolutegravir two drug regimens2023 · 17 citations
  4. 4‘Leaving no stones unturned’: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort2026
  5. 5Reasons, Efficacy and Safety of Switching to Dolutegravir-Based Regimens Among Virologically Suppressed PLWH: A Retrospective Cohort Study of 96 Weeks2024 · 7 citations